search
Back to results

In-line Filtration to Reduce Systemic Inflammatory Response Syndrome in Babies Born Very prEtErm (FRISBEE)

Primary Purpose

Babies Born Very Preterm

Status
Completed
Phase
Not Applicable
Locations
France
Study Type
Interventional
Intervention
0.2 micron positively charged PALL Corporation filters and 1.2 micro IV in-line filters used for lipid administration
Sponsored by
Assistance Publique - Hôpitaux de Paris
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional prevention trial for Babies Born Very Preterm

Eligibility Criteria

24 Weeks - 32 Weeks (Child)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Every newborn with a gestational age between 24+0 and 31+6 weeks of gestation or with a birth weight <1500 gm, born at the maternity of Robert Debré children's hospital,
  • Neonates whose parental authority holders have been informed for the study & do not opposite to participate,
  • Neonates whose parental authority holders are covered by the social security system or CMU.

Exclusion Criteria:

  • Preterm infants with a gestational age ≥ 32 weeks of gestation,
  • Congenital malformation and/or heart diseases other than patent ductus arteriosus or foramen ovale,
  • "Outborn" neonates,
  • Newborns whose parental authority holders are minor,
  • Newborns with severe birth asphyxia (cord blood pH<7.0 or Apgar score < 5 at 10 min),
  • Newborns whose parental authority holders are not beneficiaries of social security coverage.

Sites / Locations

  • Hopital Robert Debre

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

No Intervention

Arm Label

in-line filters

without in-line filters.

Arm Description

0.2 micron positively charged PALL Corporation filters for parenteral nutrition (Posidyne® NEO Intravenous Filter Set) and 1.2 micro IV in-line filters used for lipid administration (Lipipor™ NEO Filters for Neonatal Parenteral Nutrition)

Outcomes

Primary Outcome Measures

serum concentrations pattern of 4 major pro-inflammatory cytokines (IL1beta, IL6, IL8 and TNFalpha)

Secondary Outcome Measures

Full Information

First Posted
February 15, 2016
Last Updated
February 2, 2023
Sponsor
Assistance Publique - Hôpitaux de Paris
search

1. Study Identification

Unique Protocol Identification Number
NCT02686060
Brief Title
In-line Filtration to Reduce Systemic Inflammatory Response Syndrome in Babies Born Very prEtErm
Acronym
FRISBEE
Official Title
In-line Filtration to Reduce Systemic Inflammatory Response Syndrome in Babies Born Very prEtErm
Study Type
Interventional

2. Study Status

Record Verification Date
February 2018
Overall Recruitment Status
Completed
Study Start Date
April 2016 (Actual)
Primary Completion Date
October 5, 2017 (Actual)
Study Completion Date
November 2017 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Assistance Publique - Hôpitaux de Paris

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
While venous access is an essential part of caring for the preterm neonate potential severe adverse events, including contamination of fluids with bacteria, endotoxins and particulates could occur (Bethune 2001). Infusion therapy carries a risk for catheter-associated septicaemia (Geiss 1992) originated from the catheter tubing, the ports, at the cannula site or from contaminated infusion fluid. While not all infections lead to septicaemia, immuno-compromised patients such as neonates are at greater risk, and infection becomes a major problem (Ng 1989) and a major risk factor for neurodevelopmental disabilities (Volpe 2008). Indeed, it has been postulated that endotoxins may be involved in the pathogenesis of a proportion of cases of periventricular leukomalacia, the most frequent brain damage associated with neurocognitive handicaps in the human neonate (Volpe 2001). The presence of calcium in parenteral nutrition mixture leads to precipitation due to its incompatibility with the other components of the admixtures and leads to high concentration of particles (Athanasiou 2014). Adverse systemic effects of particulate matter including phlebitis, granulomata formation in the lung (Marshall 1987) and ischaemic necrosis, are a common finding in necrotizing enterocolitis another serious complication flowing preterm birth (Ballance 1990). Particle contamination of infusion solutions exists despite a stringent infusion regiment. The number and composition of particles depends on the complexity of the applied admixtures (Jack 2010). Particulate contamination is due to drug incompatibility reactions or their incomplete reconstitution during the preparation process (Schroder 1994). Various studies have demonstrated the contamination of infusion solutions with glass particles from opening glass ampoules, particles from rubber stoppers or conglomerates of the parenteral nutrition components (Ball 2003). Particles have also been shown to be inherent to generic drug formulation (Oie 2005). In an intensive care setting the particle burden may rise up to one million infused particles per day, increasing with the complexity and quantity of the administered infusions (Walpot 1989). There are two main IV filter pore sizes; the 0.2 micron filter is used for aqueous solutions, and the 1.2 micron filter is recommended for larger molecule solutions such as lipids. The 0.2 micron filter has also been reported to remove air, microorganisms and particulate matter. In addition, endotoxin retention is reportedly achieved by using a positively charged filter membrane; toxic macro-molecules are released by gram-negative bacteria and are claimed to be effective for up to ninety six hours (Bethune 2001). In-line IV filters are currently claimed to be an effective strategy for the removal of bacteria, endotoxins and particulates associated with intravenous therapy in adults (Ball 2003) and particularly effective in the removal of particles caused from drug precipitate such as antibiotics (Chee 2002; Ball 2003). However, evidence of the beneficial effect of in-line IV filters in children and neonates is much weaker, despite some positive studies (Jack 2012; Boehne 2013; Sasse 2015). In the population of preterm infants, no study is currently available while particulate contamination due to infusion therapy carries a higher health risk in this subpopulation. The benefits of using IV in-line filters in critically-ill preterm neonates remains to be demonstrated. This intervention in adults has also been challenged by several authors (Pearson 1996; Newell 1998). Friedland reported that certain drugs such as antibiotics may be retained in the filters causing a reduction in potency (Friedland 1985). On the other hand, there are no known adverse effects from the use of IV in-line filters.
Detailed Description
While venous access is an essential part of caring for the preterm neonate potential severe adverse events, including contamination of fluids with bacteria, endotoxins and particulates could occur (Bethune 2001). Infusion therapy carries a risk for catheter-associated septicaemia (Geiss 1992) originated from the catheter tubing, the ports, at the cannula site or from contaminated infusion fluid. While not all infections lead to septicaemia, immuno-compromised patients such as neonates are at greater risk, and infection becomes a major problem (Ng 1989) and a major risk factor for neurodevelopmental disabilities (Volpe 2008). Indeed, it has been postulated that endotoxins may be involved in the pathogenesis of a proportion of cases of periventricular leukomalacia, the most frequent brain damage associated with neurocognitive handicaps in the human neonate (Volpe 2001). The presence of calcium in parenteral nutrition mixture leads to precipitation due to its incompatibility with the other components of the admixtures and leads to high concentration of particles (Athanasiou 2014). Adverse systemic effects of particulate matter including phlebitis, granulomata formation in the lung (Marshall 1987) and ischaemic necrosis, are a common finding in necrotizing enterocolitis another serious complication flowing preterm birth (Ballance 1990). Particle contamination of infusion solutions exists despite a stringent infusion regiment. The number and composition of particles depends on the complexity of the applied admixtures (Jack 2010). Particulate contamination is due to drug incompatibility reactions or their incomplete reconstitution during the preparation process (Schroder 1994). Various studies have demonstrated the contamination of infusion solutions with glass particles from opening glass ampoules, particles from rubber stoppers or conglomerates of the parenteral nutrition components (Ball 2003). Particles have also been shown to be inherent to generic drug formulation (Oie 2005). In an intensive care setting the particle burden may rise up to one million infused particles per day, increasing with the complexity and quantity of the administered infusions (Walpot 1989). There are two main IV filter pore sizes; the 0.2 micron filter is used for aqueous solutions, and the 1.2 micron filter is recommended for larger molecule solutions such as lipids. The 0.2 micron filter has also been reported to remove air, microorganisms and particulate matter. In addition, endotoxin retention is reportedly achieved by using a positively charged filter membrane; toxic macro-molecules are released by gram-negative bacteria and are claimed to be effective for up to ninety six hours (Bethune 2001). In-line IV filters are currently claimed to be an effective strategy for the removal of bacteria, endotoxins and particulates associated with intravenous therapy in adults (Ball 2003) and particularly effective in the removal of particles caused from drug precipitate such as antibiotics (Chee 2002; Ball 2003). However, evidence of the beneficial effect of in-line IV filters in children and neonates is much weaker, despite some positive studies (Jack 2012; Boehne 2013; Sasse 2015). In the population of preterm infants, no study is currently available while particulate contamination due to infusion therapy carries a higher health risk in this subpopulation. The benefits of using IV in-line filters in critically-ill preterm neonates remains to be demonstrated. This intervention in adults has also been challenged by several authors (Pearson 1996; Newell 1998). Friedland reported that certain drugs such as antibiotics may be retained in the filters causing a reduction in potency (Friedland 1985). On the other hand, there are no known adverse effects from the use of IV in-line filters.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Babies Born Very Preterm

7. Study Design

Primary Purpose
Prevention
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
160 (Actual)

8. Arms, Groups, and Interventions

Arm Title
in-line filters
Arm Type
Experimental
Arm Description
0.2 micron positively charged PALL Corporation filters for parenteral nutrition (Posidyne® NEO Intravenous Filter Set) and 1.2 micro IV in-line filters used for lipid administration (Lipipor™ NEO Filters for Neonatal Parenteral Nutrition)
Arm Title
without in-line filters.
Arm Type
No Intervention
Intervention Type
Device
Intervention Name(s)
0.2 micron positively charged PALL Corporation filters and 1.2 micro IV in-line filters used for lipid administration
Primary Outcome Measure Information:
Title
serum concentrations pattern of 4 major pro-inflammatory cytokines (IL1beta, IL6, IL8 and TNFalpha)
Time Frame
18 months

10. Eligibility

Sex
All
Minimum Age & Unit of Time
24 Weeks
Maximum Age & Unit of Time
32 Weeks
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Every newborn with a gestational age between 24+0 and 31+6 weeks of gestation or with a birth weight <1500 gm, born at the maternity of Robert Debré children's hospital, Neonates whose parental authority holders have been informed for the study & do not opposite to participate, Neonates whose parental authority holders are covered by the social security system or CMU. Exclusion Criteria: Preterm infants with a gestational age ≥ 32 weeks of gestation, Congenital malformation and/or heart diseases other than patent ductus arteriosus or foramen ovale, "Outborn" neonates, Newborns whose parental authority holders are minor, Newborns with severe birth asphyxia (cord blood pH<7.0 or Apgar score < 5 at 10 min), Newborns whose parental authority holders are not beneficiaries of social security coverage.
Facility Information:
Facility Name
Hopital Robert Debre
City
Paris
ZIP/Postal Code
75019
Country
France

12. IPD Sharing Statement

Plan to Share IPD
No
Citations:
PubMed Identifier
32193413
Citation
Virlouvet AL, Pansiot J, Toumazi A, Colella M, Capewell A, Guerriero E, Storme T, Rioualen S, Bourmaud A, Biran V, Baud O. In-line filtration in very preterm neonates: a randomized controlled trial. Sci Rep. 2020 Mar 19;10(1):5003. doi: 10.1038/s41598-020-61815-4.
Results Reference
result

Learn more about this trial

In-line Filtration to Reduce Systemic Inflammatory Response Syndrome in Babies Born Very prEtErm

We'll reach out to this number within 24 hrs